Ignite Creation Date:
2025-12-26 @ 10:58 AM
Ignite Modification Date:
2026-02-27 @ 10:38 AM
Study NCT ID:
NCT02343406
Status:
COMPLETED
Last Update Posted:
2020-05-22
First Post:
2014-12-22
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
Sponsor:
AbbVie
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Glioblastoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Glioblastoma | View |
| None | Epithelial Growth Factor vIII mutation | View |
| None | Temozolomide | View |
| None | Lomustine | View |
| None | ABT-414 | View |
| None | European Organization for Research and Treatment of Cancer | View |
| None | Recurrent glioblastoma | View |
| None | Epithelial Growth Factor | View |
| None | Brain Tumor | View |
| None | Brain Tumor Group | View |
| None | Antibody Drug Conjugate | View |
| None | EORTC | View |
| None | Pediatric High Grade Gliomas | View |
| None | Pediatric Diffuse Intrinsic Pontine Glioma | View |
| None | Pediatric WHO grade III glioma | View |
| None | Pediatric WHO grade IV glioma | View |
| None | EGFR amplification | View |
| None | Children | View |